We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
C4 Therapeutics Inc
8 own
5 watching
Current Price
$4.42
$0.52
(13.33%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
173.65M
52-Week High
11.88000
52-Week Low
1.06000
Average Volume
1.61M
Dividend Yield
--
P/E Ratio
--
Market Capitalization173.65M52-Week High11.8800052-Week Low1.06000Average Volume1.61MDividend Yield--P/E Ratio--What does the C4 Therapeutics Inc do?
We are a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases.
--- We were incorporated in October 2015 under the laws of the State of Delaware. Our principal executive offices are located at 490 Arsenal Way, Suite 200, Watertown, Massachusetts 02472, and our telephone number is (617) 231-0700.We have one wholly owned subsidiary, C4T Securities Corporation, a Massachusetts corporation. Our website address is www.c4therapeutics.com.
Read More
How much money does C4 Therapeutics Inc make?
News & Events about C4 Therapeutics Inc.
Zolmax
1 year ago
C4 Therapeutics (NASDAQ:CCCC Get Rating) had its price objective trimmed by Bank of America from $11.00 to $5.00 in a report issued on Tuesday , The Fly reports. The firm currently has a neutral rating on the stock. A number of other analysts have also recently commented on CCCC. Morgan Stanley ...
Zolmax
1 year ago
C4 Therapeutics, Inc. (NASDAQ:CCCC Get Rating) Equities researchers at Brookline Capital Management dropped their FY2027 earnings estimates for C4 Therapeutics in a research report issued to clients and investors on Thursday, February 23rd. Brookline Capital Management analyst L. Cann now forecasts ...
Globe Newswire
1 year ago
WATERTOWN, Mass., Jan. 30, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today ...
Globe Newswire
1 year ago
Phase 1/2 Trial of CFT7455, an IKZF1/3 MonoDAC Degrader, Continues to Progress with Phase 1 Dose Escalation Data Expected in 2H 2023; Enrollment Open for Arm Evaluating CFT7455 in Combination with Dexamethasone Phase 1/2 Trial of CFT8634, a BRD9 BiDAC Degrader, Continues to Progress with Phase 1 ...
Ticker Report
2years ago
Vickers Vantage Corp. I (NASDAQ:VCKA Get Rating) and C4 Therapeutics (NASDAQ:CCCC Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability...
Frequently Asked Questions
Frequently Asked Questions
What is C4 Therapeutics Inc share price today?
Can Indians buy C4 Therapeutics Inc shares?
How can I buy C4 Therapeutics Inc shares from India?
Can Fractional shares of C4 Therapeutics Inc be purchased?
What are the documents required to start investing in C4 Therapeutics Inc stocks?
What is today’s traded volume of C4 Therapeutics Inc?
What is today’s market capitalisation of C4 Therapeutics Inc?
What is the 52-Week High and Low Range of C4 Therapeutics Inc?
What percentage is C4 Therapeutics Inc down from its 52-Week High?
What percentage is C4 Therapeutics Inc up from its 52-Week Low?
Current Price
$4.42
$0.52
(13.33%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.